PMDA drug package insert
エクメット配合錠LD
PMDA Prescription drug · ノバルティスファーマ株式会社 · package insert Jan 1, 2026
Key facts
| Brand names | エクメット配合錠LD, エクメット配合錠HD |
|---|---|
| Nonproprietary names | ビルダグリプチン・メトホルミン塩酸塩配合剤 |
| Companies | 製造販売／ノバルティスファーマ株式会社 |
| Product type | Prescription drug |
| Therapeutic category | 選択的DPP-4阻害薬/ビグアナイド系薬配合剤 ［2型糖尿病治療薬］ |
| Therapeutic category codes | 873969 |
| YJ codes | 3969104F1029, 3969104F2025 |
| Approval numbers | 22700AMX01016000, 22700AMX01017000 |
| Package insert edition | 第7版 |
| Package insert date | Jan 1, 2026 |
| PMDA document key | 300242_3969104F1029_1 |
| PMDA company code | 300242 |
At a glance
- 1–9 Package insert revisions
- 10–99 Related PMDA documents
- 1–9 Safety communications
- Yes PMDA review report published
- No Risk management plan (RMP)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMDA approved drugs and package inserts (Japan)
Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.
Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date: